移植技術と研究

Translational Potential of Cell Treatment in Neonatal

Abstract

Luz Elena Duran-Carabali

Neonatal hypoxia ischemia (HI) is still a leading cause of death and is linked to a high rate of life-long impairments. Unfortunately, there is little clinical treatment for HI, and no existing intervention can successfully prevent the long-term effects of HI injury. Only hypothermia has some positive effects on moderately affected HI children at this time. To improve the translational potential of cell treatment in neonatal HI, investigations should closely resemble clinical trials. Furthermore, the cell type, dose, administration schedule, and delivery channel should all be considered and determined in the experimental design. Despite these suggestions, intraparenchymal injection remains the most widely used cell delivery method in the United States.